Primo Nutraceuticals Inc.
Other OTCTotal Valuation
Primo Nutraceuticals Inc. carries a market capitalization of 26.00, placing it among publicly traded companies globally. Its enterprise value stands at 2.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 26.00 |
| Enterprise Value | 2.40M |
Share Statistics
Primo Nutraceuticals Inc. currently has 10.09M shares outstanding.
| Shares Outstanding | 10.09M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 4.05 |
| P/TBV Ratio | 3.46 |
| P/FCF Ratio | -1.24 |
| P/OCF Ratio | -1.37 |
Financial Position
Primo Nutraceuticals Inc. maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | 83.01 |
| Debt / EBITDA | -0.31 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -736.81 |
| Return on Assets (ROA) | -154.71 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Income Statement
EBITDA reached -1.50M, while operating income came in at -1.50M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -1.50M |
| Pretax Income | -3.84M |
| Net Income | -3.84M |
| EBITDA | -1.50M |
| EBIT | -1.50M |
| Earnings Per Share (EPS) | -0.46 |
Balance Sheet
Primo Nutraceuticals Inc. holds 9,949.00 in cash and equivalents against 465,925.00 in total debt, resulting in a net debt position of 461,380.00. Total book value stands at 478,839.00, with working capital of -2.61M providing operational flexibility.
| Cash & Cash Equivalents | 9,949.00 |
| Total Debt | 465,925.00 |
| Net Debt | 461,380.00 |
| Equity (Book Value) | 478,839.00 |
| Book Value Per Share | 0.06 |
| Working Capital | -2.61M |
Cash Flow
Primo Nutraceuticals Inc. produced -1.41M in operating cash flow over the past twelve months. After subtracting 153,695.00 in capital expenditures, free cash flow totaled -1.26M - equivalent to -0.15 per share.
| Operating Cash Flow | -1.41M |
| Capital Expenditures | 153,695.00 |
| Free Cash Flow | -1.26M |
| FCF Per Share | -0.15 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -81.31 |
| FCF Yield | -80.70 |
Stock Splits
Primo Nutraceuticals Inc.'s most recent stock split took place on August 26, 2020 with a 15:1 split ratio.
| Last Split Date | 8/26/2020 |
| Split Ratio | 15:1 |
Scores
Primo Nutraceuticals Inc. posts an Altman Z-Score of -5.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.24 |